Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.

Jessen, Frank; Wolfsgruber, Steffen; Kleineindam, Luca; Spottke, Annika; Altenstein, Slawek; Bartels, Claudia; Berger, Moritz; Brosseron, Frederic; Daamen, Marcel; Dichgans, Martin; Dobisch, Laura; Ewers, Michael; Fenski, Friederike; Fliessbach, Klaus; Freiesleben, Silka D; Glanz, Wenzel; Görß, Doreen; Gürsel, Selim; Janowitz, Daniel; Kilimann, Ingo; Kobeleva, Xenia; Lohse, Andrea; Maier, Franziska; Metzger, Coraline; Munk, Matthias; Preis, Lukas; Sanzenbacher, Carolin; Spruth, Eike; Rauchmann, Boris; Vukovich, Ruth; Yakupov, Renat; Weyrauch, Anne-Sophie; Ziegler, Gabriel; Schmid, Matthias; Laske, Christoph; Perneczky, Robert; Schneider, Anja; Wiltfang, Jens; Teipel, Stefan; Bürger, Katharina; Priller, Josef; Peters, Oliver; Ramirez, Alfredo; Boecker, Henning; Heneka, Michael T; Wagner, Michael; Düzel, Emrah     «

Jessen, Frank; Wolfsgruber, Steffen; Kleineindam, Luca; Spottke, Annika; Altenstein, Slawek; Bartels, Claudia; Berger, Moritz; Brosseron, Frederic; Daamen, Marcel; Dichgans, Martin; Dobisch, Laura; Ewers, Michael; Fenski, Friederike; Fliessbach, Klaus; Freiesleben, Silka D; Glanz, Wenzel; Görß, Doreen; Gürsel, Selim; Janowitz, Daniel; Kilimann, Ingo; Kobeleva, Xenia; Lohse, Andrea; Maier, Franziska; Metzger, Coraline; Munk, Matthias; Preis, Lukas; Sanzenbacher, Carolin; Spruth, Eike; Rauchmann,...     »

INTRODUCTION: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. METHODS: Cross-sectional and longitudinal data from the multicenter, memory clinic-based DELCODE study. RESULTS: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD-A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO-A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. DISCUSSION: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.      «

INTRODUCTION: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. METHODS: Cross-sectional and longitudinal data from the multicenter, memory clinic-based DELCODE study. RESULTS: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD-A+ cases (39.3% of all SCD) showed g...     »